Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07501845 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Registry Maastro Applicator

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints added 9 → 11 primary endpoints
See other at-risk trials from Maastricht Radiation Oncology

Record History

  1. Primary endpoint(s) modified Eligibility criteria expanded, about 5 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 5 words
  2. Recruitment opened Study sites: 0 to 1 · Start date changed from estimate of Mar 15, 2026 to Mar 23, 2026v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 15, 2026 to Mar 23, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This registry will collect data from all patients treated with the MAASTRO HDR applicator. The goal is to deepen knowledge about dose-response relationships in rectal cancer boosting, which is essential for improving future treatment approaches and patient selection.
Trial Details
NCT Number NCT07501845
Lead Sponsor Maastricht Radiation Oncology
Conditions Rectal Cancer
Enrollment 999 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov